Phibro Animal Health (NASDAQ:PAHC) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Phibro Animal Health (NASDAQ:PAHC) issued its quarterly earnings results on Wednesday. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.14, FiscalAI reports. The firm had revenue of $396.75 million for the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%. Phibro Animal Health updated its FY 2027 guidance to 3.410-3.590 EPS.

Phibro Animal Health Price Performance

Shares of PAHC stock traded up $0.16 during trading hours on Wednesday, hitting $36.09. The stock had a trading volume of 287,583 shares, compared to its average volume of 295,650. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 0.50 and a beta of 0.46. Phibro Animal Health has a one year low of $28.25 and a one year high of $60.08. The stock’s 50-day moving average price is $33.84 and its two-hundred day moving average price is $42.54.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 20.60%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Citigroup lowered their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Finally, Weiss Ratings cut shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and an average target price of $42.50.

Institutional Trading of Phibro Animal Health

Large investors have recently made changes to their positions in the business. State Street Corp lifted its holdings in shares of Phibro Animal Health by 5.4% in the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after acquiring an additional 48,243 shares during the last quarter. Millennium Management LLC increased its position in Phibro Animal Health by 4,227.1% during the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after acquiring an additional 626,492 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Phibro Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after acquiring an additional 21,951 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Phibro Animal Health by 1.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock worth $18,394,000 after purchasing an additional 6,826 shares during the period. Finally, Invesco Ltd. grew its holdings in Phibro Animal Health by 22.5% during the 3rd quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock valued at $13,040,000 after purchasing an additional 59,226 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.